The company's worst days might be behind it.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Madrigal Pharmaceuticals is relocating to a larger West Conshy headquarters as sales surge and its MASH treatment drives ...

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today ...

Resmetirom effectively resolves MASH and improves fibrosis, independent of GLP-1 or SGLT2 inhibitor use, in patients with T2DM. Achieving ≥5% weight loss enhances resmetirom's effects on MASH ...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Inventiva secured an upsized US$150m on Wednesday from an overnight stock sale that fully funds an ongoing Phase III trial of its promising MASH drug. Leerink Partners and Piper Sandler priced 38.9m ...

Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...